CinPhloro Pharma

CinPhloro Pharma, a portfolio company of CinRx, is dedicated to developing the first safe, effective, and long-term treatment for Irritable Bowel Syndrome with predominant diarrhea (IBS-D). CinPhloro's CIN-103 is a new formulation of phloroglucinol, a small molecule used in certain countries to relieve symptoms of functional gastrointestinal disorders. CIN-103 is modified to address the shortcomings of phloroglucinol, including its short half-life, and targets multiple IBS-D action points, including motility, secretion, pain, spasms, and inflammation.